Literature DB >> 9156271

Allogeneic peripheral blood stem cell transplant for myelodysplasia after chemotherapy for post-transplant lymphoma in a cardiac transplant recipient at 10 years.

J Lister1, J K Simpson, M M deMagalhaes-Silverman, W B Rybka, A D Donnenberg, D J Myers, E D Ball.   

Abstract

A 32-year-old male received an allogeneic peripheral blood stem cell transplant (alloPBSCT) for myelodysplasia from his one HLA-A antigen mismatched brother. He is alive with trilineage engraftment and without active GVHD 200 days after transplant. In July 1986 he underwent orthotopic cardiac transplantation for viral cardiomyopathy and has received continuous immunosuppressive therapy. A post-transplant lymphoproliferative disorder with Hodgkin-like histopathology was diagnosed in August 1993 and was successfully treated with four cycles of MOPP chemotherapy. Due to persistent pancytopenia he underwent a bone marrow aspiration and biopsy in May 1996 which revealed monosomy 7 and morphologic changes compatible with myelodysplasia. This is the first report of a cardiac transplant recipient receiving an allogeneic hematopoietic stem cell transplant.

Entities:  

Mesh:

Year:  1997        PMID: 9156271     DOI: 10.1038/sj.bmt.1700758

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  2 in total

1.  Classical Hodgkin lymphoma type post-transplant lymphoproliferative disorder in a kidney transplant recipient: a diagnostic pitfall.

Authors:  Taro Mohri; Yoshihiro Ikura; Asako Hirakoso; Masashi Okamoto; Masakatsu Hishizawa; Akifumi Takaori-Kondo; Seiichi Kato; Shigeo Nakamura; Kai Yoshimura; Hidetoshi Okabe; Yasuhiro Iwai
Journal:  Int J Hematol       Date:  2018-01-29       Impact factor: 2.490

2.  Allogeneic Hematopoietic Cell Transplantation for Therapy-Related Myeloid Leukemia following Orthotopic Cardiac Transplantation.

Authors:  Richard J Lin; Richard A Larson; Koen van Besien; Elizabeth S Rich
Journal:  Case Rep Hematol       Date:  2013-03-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.